Thinle Chodon to Melanoma
This is a "connection" page, showing publications Thinle Chodon has written about Melanoma.
Connection Strength
1.523
-
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65.
Score: 0.356
-
Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. J Immunother. 2018 Jun; 41(5):248-259.
Score: 0.119
-
PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203.
Score: 0.101
-
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014 Jul 01; 20(13):3446-57.
Score: 0.090
-
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79.
Score: 0.087
-
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93.
Score: 0.087
-
Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829.
Score: 0.087
-
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29.
Score: 0.083
-
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.
Score: 0.079
-
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724.
Score: 0.077
-
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8.
Score: 0.071
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7.
Score: 0.071
-
Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15; 5(9):e12711.
Score: 0.070
-
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009 May 20; 7:35.
Score: 0.064
-
Identification of a novel gelsolin truncate in the vertical and metastatic phase malignant melanomas. Melanoma Res. 2002 Dec; 12(6):523-8.
Score: 0.041
-
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32.
Score: 0.022
-
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47.
Score: 0.017